Association Between IL-6 Concentration and Diabetes-Related Variables in DM1 Patients with and without Microvascular Complications by unknown
Association Between IL-6 Concentration and Diabetes-Related
Variables in DM1 Patients with and without Microvascular
Complications
Malgorzata Wegner,1,3 Aleksandra Araszkiewicz,2 Maria Piorunska-Stolzmann,1
Bogna Wierusz-Wysocka,2 and Dorota Zozulinska-Ziolkiewicz2
Abstract—Interleukin 6 (IL-6) plays an important role in the initiation and acceleration of chronic
inﬂammation and could contribute to development of microvascular complications in patients with
type 1 diabetes (DM1). Therefore, this study was aimed to investigate the association between
concentration of IL-6 in relation to glucose control, lipid proﬁle, and body mass index (BMI) in 69
DM1 patients subdivided according to the absence or presence of microvascular complications.
BMI, level of fasting plasma glucose (FPG), and concentrations of total cholesterol (TCH), LDL
cholesterol (LDL-C), and IL-6 were higher in DM1 patients compared to the control group. In DM1
patients, IL-6 concentration was positively correlated with level of FPG, LDL-C, TCH concen-
trations, and BMI. These correlations were stronger in the subgroup of patients with microvascular
complications. In addition, BMI independently inﬂuences IL-6 concentration in DM1 patients. In
conclusion, elevated IL-6 concentration is associated with diabetes-related variables which could
accelerate progression of microvascular complications in DM1 patients.
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INTRODUCTION
Chronic vascular complications are the major cause
of death in patients with type 1 diabetes (DM1) [1].
However, hyperglycemia seems to be the most critical
parameter for development of chronic complications in
diabetic patients [2]; the amount of evidences that other
factors contribute to this process increase subsequently
[3, 4].
Recently, it has been shown that patients with DM1
demonstrate higher levels of proinﬂammatory markers
which are associated with atherosclerotic plaque forma-
tion and endothelial dysfunction [5, 6]. These indicate
that an enhanced low-grade inﬂammatory process may
accelerate development of microvascular and macro-
vascular complications in DM1 patients [7].
One of the markers of inﬂammation is interleukin 6
(IL-6) [8]. It is a pleiotropic cytokine, produced mostly by
adipocytes, ﬁbroblast, endothelial cells, and activated
leukocytes and monocytes [9]. IL-6 mainly is known as a
chief regulator of acute-phase inﬂammatory response [10].
However, a critical role of IL-6 in the transformation from
acute to chronic inﬂammation was established as well [11].
In patients with DM1, the concentration of IL-6 has
been shown to be normal [12] or higher [13] compared
to healthy people. Moreover, some studies suggest that
IL-6 participates in the initiation and acceleration of the
chronic inﬂammation process and could contribute to
development of micro- and macrovascular complications
in diabetic patients [14, 15].
Therefore, this study was aimed to investigate the
association between concentration of IL-6 in relation to
glucose control, lipid proﬁle, and body mass index
(BMI) in DM1 patients subdivided according to absence
or presence of microvascular complications.
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The study group consisted of 69 patients with DM1
recruited by the Department of Internal Medicine and
Diabetology at Poznan University of Medical Sciences
and participating in the Poznan Prospective Study
(NCT01411033) [16]. DM1 was diagnosed according to
the criteria from the American Diabetes Association on the
basis of classical symptoms, blood glucose concentration
higher than 11.1 mmol/l, and C-peptide concentration
lower than 0.5 μg/l [17]. All patients were treated with
intensive insulin therapy from the onset of the disease. In
addition, 13 DM1 patients have been treated with
angiotensin-converting enzyme inhibitors (ACE-I) after
diagnosis of diabetic kidney disease. The study group was
divided according to the absence or presence of chronic
microvascular diabetic complications, i.e., retinopathy,
diabetic kidney disease, and neuropathy.
Diabetic retinopathy was diagnosed by direct
ophthalmoscopy through dilated pupils followed by
fundus photography in all patients. Diabetic retinopathy
was graded according to the classiﬁcation of the
American Academy of Ophthalmology into no retinop-
athy; mild, moderate, and severe nonproliferative reti-
nopathy; and proliferative retinopathy [18].
Diabetic kidney disease was detected at the stage of
albuminuria (urinary albumin excretion rate between 30
and 300 mg/24 h in two samples collected over a 3-
month period after exclusion of secondary causes of
microproteinuria. Diabetic kidney disease was deﬁned as
the presence of albuminuria in connection with diabetes
of over 10 years in duration or with diagnosed diabetic
retinopathy [19].
Diabetic neuropathy was diagnosed in patients with
two or more of the following components: the presence
of symptoms of neuropathy, the absence of ankle tendon
reﬂexes, and abnormal scores for pressure and/or
vibration perception [17].
The control group consisted of 18 healthy subjects.
They were characterized by reference BMI, lipid proﬁle,
and glucose concentration. All subjects gave informed
consent, and the Ethical Committee of the Poznan Univer-
sity of Medical Sciences approved the study protocol.
Collection of Blood Samples
Blood samples were collected between 8:00 and
10:00 am after a 12-h fast in tubes without anticoagulant
using a standard venipuncture technique. The samples
were allowed to clot at room temperature and then
centrifuged at 2,000×g for 15 min to obtain serum. Basic
clinical analysis was performed during the same day
blood was taken. Subsequently, 1 ml of serum was
stored at −80 °C until measurement of IL-6 was
performed.
Measurements
The serum concentrations of triglycerides (TG), total
cholesterol (TCH), HDL cholesterol (HDL-C), and fasting
plasma concentration of glucose (FPG) were determined
using the commercially available assay kits (Roche,
Switzerland). LDL cholesterol (LDL-C) level was obtained
using the following formula: LDL-C0TC−HDL-C−TG/
5. Postprandial plasma glycemia (PPG) was calculated as
the mean of plasma concentration of glucose 2 h after three
main meals in self-control from 3 days before recruitment.
The glycated hemoglobin c (HbA1c) value was measured
using high-performance liquid chromatography with the
Variant Hemoglobin A1c Program (Bio-Rad Laboratories,
Hercules, CA, USA) [20].
The serum IL-6 concentration was measured by
enzyme-linked immunosorbent assay (human IL-6
ELISA, Mabtech, Sweden) according to the manufactur-
er's instruction. The detection limit was 1 pg/ml, intra-
assay coefﬁcient of variation (CV) was 2.5 %, and
interassay CV was 2.8 %.
Statistical Analysis
Data are expressed as mean ± standard deviation
(SD) for normal distribution or median with interquartile
range for non-normal distribution. Age, BMI, and
systolic and diastolic blood pressure levels were com-
pared between patients with DM1 and the control group
by Student's t test. In addition, this test was used to
compare diabetes duration between DM1 patients with
and without chronic complications. The Mann–Whitney
test was performed to detect differences in biochemical
parameters and serum IL-6 concentration between
patients with DM1 and the control group. Moreover,
this test was used to compare levels of PPG and HbA1c
between DM1 patients without (DM) and with (DMC)
chronic microvascular complications. Analysis of vari-
ance was used to establish differences of age between
patients with and without microvascular complications
and the control group. The Kruskal–Wallis test was
performed to determine the differences of biochemical
parameters and IL-6 concentration between DM1
patients without and with microvascular complications
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and the control group. The Spearman correlation
coefﬁcient was used to test the strength of any
associations between different variables. In addition,
multivariate regression analysis was used to determine
which of the selected variables (gender, age, diabetes
duration, and BMI level) primarily affect IL-6 concen-
trations in patients with DM1. A similar analysis was
performed to check which parameters of lipid proﬁle
independently inﬂuence IL-6 concentration in DM1
patients. A p value lower than 0.05 was accepted as
statistically signiﬁcant.
RESULTS
Clinical Characteristics of DM1 Patients
There were 24 women and 45 men among
Polish patients with DM1. Their mean age was
35.4±6.3 years, and the mean diabetes duration was
12.5±1.5 years.
In 39 patients (14 women, 25 men), microvas-
cular complications were diagnosed, i.e., retinopathy
(n015), diabetic kidney disease (n013), and neurop-
athy (n011). Therefore, DM1 patients were subdi-
vided into two subgroups according to absence (DM)
or presence (DMC) of chronic microvascular compli-
cations.
To identify the differences of levels of basic
clinical and biochemical variables that could arise
from presence of microvascular complications, the
two subgroups of DM1 patients were compared with
18 nondiabetic age/gender-matched subjects in the
control group (eight women, ten men; 32.1±
10.8 years). It was found that DM1 patients without
and with microvascular complications did not differ
according to TG and HDL concentration and systolic
(SBP) and diastolic blood pressure (DBP) compared
to healthy subjects. FPG level was much higher in
DM1 patients from both subgroups in comparison to
healthy people. Glycemic control for most DM1
patients was not satisfactory to maintain good
metabolic control. Moreover, DM1 patients from both
subgroups had higher BMI than the control group. In
addition, DM1 patients with microvascular complica-
tions showed higher TCH and LDL-C in comparison
to the control group. Signiﬁcant differences for these
parameters were not established between DM1
patients without microvascular complications and the
control group. HbA1c value was higher in DM1
patients with microvascular complications compared
to patients without them (results presented in Table 1).
The Concentration of IL-6 in DM1 Patients
It was shown that DM1 patients with microvascular
complications had higher IL-6 concentration compared
to the control group, whereas the concentration of IL-6
did not differ signiﬁcantly between DM1 patients
without microvascular complications and the control
group (Fig. 1).
Table 1. Characteristic of DM1 Patients without (DM) and with (DMC) Microvascular Complications and the Control Group
DM DMC Healthy group
p valuen030 n039 n018
Sex (F/M) 10/20 14/25 8/10 NS
Age (years) 34.9±5.4 35.8±3.4 32.1±10.8 NS
BMI (kg/m2) 24.2±3.5a 25.4±4.1a 21.1±1.8 0.0001
FPG (mmol/l) 8.8 (7.3–9.0)a 9.1 (7.6–9.9)a 4.1 (3.2–4.4) 0.000001
PPG (mmol/l) 8.9 (7.2–9.3) 9.2 (8.7–9.7) – NS
HbA1C (%) 7.9 (7.1–8.8) 8.6 (8.2–9.6)
b – 0.001
TG (mmol/l) 0.9 (0.7–1.0) 1.0 (0.7–1.5) 1.0 (0.7–1.1) NS
TCH (mmol/l) 4.4 (4.2–4.9) 5.1 (4.5–5.6)a 4.0 (3.9–4.5) 0.0004
LDL-C (mmol/l) 2.6 (2.2–3.1) 3.0 (2.4–3.4)a 2.2 (1.8–2.3) 0.008
HDL-C (mmol/l) 1.5 (1.5–1.8) 1.6 (1.4–1.9) 1.3 (0.9–1.4) NS
SBP (mmHg) 115 (110–120) 118 (112–130) 105 (99–110) NS
DBP (mmHg) 81 (79–85) 83 (80–85) 75 (73–76) NS
BMI body mass index, DBP diastolic blood pressure, FPG fasting plasma glucose, HbA1c glycated hemoglobin A1c, HDL-C HDL cholesterol, LDL-C
LDL cholesterol, PPG postprandial plasma glucose, SBP systolic blood pressure, TCH total cholesterol level, TG triglycerides, NS statistically not
signiﬁcant
a Statistical signiﬁcance versus the control group
b Statistical signiﬁcance versus the group without microvascular complications
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Correlations of IL-6 Concentration
With Diabetes-Related Variables in DM1 Patients
Another interest of the study was to ascertain the
associations between diabetes-related variables and IL-6
concentration in DM1 patients. IL-6 concentration posi-
tively correlated with FPG level and LDL-C and TCH
concentration (r00.340, r00.434, r00.399; p<0.05;
n069, respectively). In addition, a strong correlation
between IL-6 concentration and BMI has been found
(r00.542, p<0.05, n069).
When we looked at these associations separately in
DM1 patients without and with microvascular compli-
cations, distinct differences were found (Table 2). In
addition, in the control group, a positive correlation has
been established between level of IL-6 and BMI
(r00.465, p<0.05, n018). Moreover, the result of
multivariate regression analysis showed that BMI inde-
pendently inﬂuences the IL-6 concentration (β00.446,
R200.300, p<0.05) in DM1 patients.
DISCUSSION
Chronic inﬂammation could be one of the reasons
of endothelial dysfunction and atherosclerotic plaque
formation, processes which contribute to the develop-
ment of micro- and macrovascular complications in
patients with diabetes [21]. Elevated IL-6 concentration
in the studied group indicates that in DM1 patients,
chronic ongoing inﬂammatory process is present [22].
Moreover, it is shown that not only chronic hyperglyce-
mia but also lipid abnormalities and elevated BMI
accelerate development of this process in patients with
DM1. It is aligned with other studies, in which similar
associations have been found [23, 24].
Observed positive correlation between FPG level
and IL-6 serum concentration in DM1 patients is
conﬁrmed by the result of an in vitro study, in which
has been found that high concentration of glucose
induces IL-6 production [4]. This can be explained by
the fact, that persistent hyperglycemia contributes to the
formation of advanced glycation end products, whose
important role in the development of chronic inﬂamma-
tion has already been proved [25].
A strong association between IL-6 concentration
and BMI in DM1 patients and in healthy people and the
result of multivariable analysis indicate that increased
weight strongly inﬂuences development of chronic
inﬂammation regardless of any additional clinical or
biochemical factors [26]. This ﬁnding is coherent with
the result of the in vitro study in which enhanced
production of IL-6 by human umbilical venous endo-
thelial cells after adding the extract of adipocytes has
been shown [27]. Moreover, our results conﬁrm that IL-
6 is the strong adipocyte-secreted factor [28].
In addition, the positive relation between BMI and
IL-6 concentration and between TCH and IL-6 serum
concentration suggests that IL-6 can act as a systemic
regulator of body mass. It has been shown that IL-6 can
reduce lipoprotein lipase activity [29], which may down-
regulate adipose tissue triglyceride deposition and
promote futile cycling and probably modulates the
actions of leptin, a molecule that controls energy
balance by causing changes in food intake and
physical activity [30]. Therefore, our results show
that an elevated level of IL-6 is associated with























Fig. 1. IL-6 concentration in DM1 patients without (DM) and with
(DMC) microvascular complications and the control group; *p00.0038,
statistically signiﬁcant versus the control group.
Table 2. The Correlations Between IL-6 Concentration and Diabetes-




p valueDM (n031) DMC (n039)
FPG (mmol/l) NS 0.655 <0.05
LDL-C (mmol/l) 0.423 0.456 <0.05
TCH (mmol/l) NS 0.402 <0.05
BMI (kg/m2) 0.427 0.738 <0.05
r Pearson's correlation coefﬁcient
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Moreover, we indicate that not only poor glycemic
control [33] but also enhanced production of IL-6 may
contribute to the development of microvascular complica-
tions in DM1 patients. It could be due to the fact that IL-6
participates in pathogenesis of endothelial dysfunction by
stimulation of monocyte chemotactic protein-1 and cell
adhesion molecules, such as intercellular adhesion mole-
cule 1 and vascular cell adhesion molecule 1 in endothelial
cells [34]. Our proposed explanation is consistent with
results of clinical and in vitro studies which found that an
enhanced level of IL-6 contributes to the endothelial cell
dysfunction [35] and accelerates the development of
chronic micro- and macrovascular complications [13, 36].
Moreover, some clinical results strongly suggest that
enhanced IL-6 concentration is most associated with the
development of diabetic kidney disease [37]. It seems this
could be related to enhanced stimulation of mesangial cell
proliferation and interferes with the extracellular dynamics
of matrix formation at the podocyte level by IL-6 [38].
However, there is a limitation that needs to be
acknowledged and addressed regarding the present
study. For assessment of the inﬂuence of IL-6
concentration on the acceleration of development of
particular chronic complications such as retinopathy,
neuropathy, and chronic kidney disease, the size of
subgroups of DM1 patients with diagnosed chronic
complications should be larger. Moreover, we cannot
exclude the potential positive effect of treatment of
DM1 patients with diabetic kidney disease with
ACE-I on the inhibition of chronic inﬂammation
process, which was already proved in patients with
DM2 [39].
In conclusion, our results provide evidence that
elevated IL-6 serum concentration is associated with
diabetes-related variables, which could accelerate pro-
gression of microvascular complications in DM1
patients.
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